ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00759200
Recruitment Status : Completed
First Posted : September 25, 2008
Last Update Posted : November 16, 2016
Sponsor:
Collaborator:
Human Genome Sciences Inc.
Information provided by:
Novartis